Assessment of cardiovascular risk and choice of antihypertensive therapy

Current Hypertension Reports

Volumn 6, Issue 5, 2004, Pages 346-351

  Kannel, William Bill ^a   Vasan, Ramachandran S ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; THIAZIDE DIURETIC AGENT;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG CHOICE; DRUG EFFICACY; EXERCISE; HUMAN; HYPERTENSION; MEDICAL ASSESSMENT; METABOLIC SYNDROME X; MULTIVARIATE ANALYSIS; OBESITY; PRACTICE GUIDELINE; WEIGHT REDUCTION;

EID: 5444232558     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-004-0052-2     Document Type: Article

References (39)

1. Chobanian AV, Bakris GL, Black HR, et al.: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC 7 Report. JAMA 2003, 289: 2560-2572.
2. NCEP Expert Panel: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP): expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001, 285: 2486-2497.
3. Laurent S: Guidelines from the British Hypertension Society: the lower the blood pressure the better. BMJ 2004, 328: 593-594.
4. Williams B, Poulter NR, Brown MJ, et al.: Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society. 2004-BHS IV. J Hum Hypertens 2004, 18: 139-185.
5. Wilson PWF, D'Agostino RB, Levy D, et al.: Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97: 1837-1847.
6. 2003 European Society of Hypertension-Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003, 21: 1011-1053.
7. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003, 21: 1983-1992.
8. Lemogoum D, Seedat YK, Mabadeje AF, et al.: Recommendations for prevention, diagnosis and management of hypertension and cardiovascular risk factors in sub-Saharan Africa. J Hypertens 2003, 21: 1993-2000.
9. Wing LMH, Reid CM, Ryan P, et al.: A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly. The Second Australian National Blood Pressure Study Group. N Engl J Med 2003, 348: 583-592.
10. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288: 2981-2997.
11. Dahlof B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE): a randomized trial against atenolol. Lancet 2002, 359: 995-1003.
12. Lithell H, Hansson L, Skoog I, et al.: The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003, 21: 875-886.
13. Grassi G, Seraville G, Dell-Oro R, et al.: Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 2003, 21: 1761-1769.
14. Lindholm LH, Persson M, Alaupovic P, et al.: Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003, 21: 1563-1574.
15. Dunder K, Lind L, Zethelius B, et al.: Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction: population-based cohort study. BMJ 2003, 326: 681-685.
16. Fretheim A, Oxman AD, Treweek S, Bjorndal A: Rational prescribing in primary care (RaPP-trial): a randomized trial of a tailored intervention to improve prescribing of antihypertensive and cholesterol-lowering drugs in general practice. BMC Health Serv Res 2003, 3: 5.
17. Stamler J: Epidemic obesity in the United States. Arch Intern Med 1993, 153: 1040-1044.
18. Mokdad AH, Ford ES, Bowman BA, et al.: Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003, 289: 76-79.
19. Horm J, Anderson K: Who in America is trying to lose weight? Ann Intern Med 1993, 119: 672-676.
20. Williamson DF: Descriptive epidemiology of body weight and weight change in U.S. adults. Ann Intern Med 1993, 119: 646-649.
21. Keys A, Menotti A, Aravanis C: 2289 deaths in 15 years. The Seven Countries study. Prev Med 1984, 13: 141-154.
22. Mann GV: The influence of obesity on health (part 2). N Engl J Med 1974, 291: 226-232.
23. Barrett-Conner EL: Obesity, atherosclerosis and coronary artery disease. Ann Intern Med 1985, 103: 1010-1019.
24. Ashley FW Jr, Kannel WB: Relation of weight change to changes in atherogenic traits: the Framingham Study. J Chronic Dis 1974, 27: 103-114.
25. Kannel WB, Wilson PW, Nam B-H, D'Agostino RB: Risk stratification of obesity as a coronary risk factor. Am J Cardiol 2002, 90: 697-701.
26. Reaven GM: Importance of identifying the overweight patient who will benefit the most by losing weight. Ann Intern Med 2003, 138: 420-423.
27. Neter JE, Stam BE, Kok FJ, et al.: Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2003, 42: 878-884.
28. Sorof J, Daniels S: Obesity hypertension in children: a problem of epidemic proportions. Hypertension 2002, 40: 441-447.
29. Gordon T, Kannel WB: The effects of overweight on cardiovascular diseases. Geriatrics 1973, 28: 80-88.
30. Ehen BJ, Todaro JF, Niaura R, et al.: Are metabolic risk factors one unified syndrome? Modeling the structure of the metabolic syndrome X. Am J Epidemiol 2003, 157: 701-711.
31. Wong ND, Pio JR, Franklin SS, et al.: Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome. Am J Cardiol 2003, 91: 1421-1426.
32. Sowers JR: Recommendations for special populations: diabetes mellitus and the metabolic syndrome. Am J Hypertens 2003, 16(Suppl): 41-45.
33. Ninomiya JK, L'Italien G, Criqui MH, et al.: Association of the metabolic syndrome with history of myocardial infarction and stroke in the third national health and nutrition examination survey. Circulation 2004, 109: 42-46.
34. Meigs JB, Wilson PW, Nathan DM, et al.: Prevalence and characteristics of the metabolic syndrome in the San Antonio and Framingham Offspring Studies. Diabetes 2003, 52: 2160-2167.
35. Port S, Demer L, Jennrich R, et al.: Systolic blood pressure and mortality. Lancet 2000, 355: 175-180.
36. Kannel WB, Vasan RS, Levy D: Is the relation of systolic blood pressure to risk of cardiovascular disease continuous and graded, or are there critical values? Hypertension 2003, 42: 453-456.
37. Neaton JD, Kuller L, Stamler J, Wentworth DN: Impact of systolic and diastolic blood pressure on cardiovascular mortality. In Hypertension: Pathophysiology, Diagnosis and Management, edn 2. Edited by Laragh JH, Brenner BM. New York: Raven Press; 1995:127-144.
38. Prospective Studies Collaboration: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360: 1903-1913.
39. Kannel WB: Risk stratification of hypertension: new insights from the Framingham Study. Am J Hypertens 2000, 13: 3S-10S.